
Sign up to save your podcasts
Or


November 2026: Contributing Editor Jesse Hinckley interviews Lindsay M. Squeglia on a randomized clinical trial where treatment-seeking youths with alcohol use disorder (N = 126) were randomized to receive either N-acetylcysteine, a supplement that is a potential pharmacotherapy, or placebo.
October 2026: Contributing Editor Jesse Hinckley interviews Lindsay M. Squeglia on a randomized clinical trial where treatment-seeking youths with alcohol use disorder (N = 126) were randomized to receive either N-acetylcysteine, a supplement that is a potential pharmacotherapy, or placebo.
September 2026: Contributing Editor Aarya K. Rajalakshmi interviews Joan R. Asarnow on the evaluation of effectiveness in reducing suicide attempt and self-harm risk on a randomized trial of 301 youth aged 12 to 24 at risk for suicide.
June 2026: Contributing Editor Shinnyi Chou interviews Meghan E. Byrne on a double-blind randomized controlled trial that examined treatment efficacy data from 121 youth (ages 8-17 years) with anxiety disorders assigned to either active or sham attention bias modification training (ABMT) alongside manualized cognitive behavioral therapy (CBT).
July 2026: Contributing Editor Narpinder Kaur Malhi interviews Teresa G. Vargas and Randi M. Schuster on a study that collected information from 30,000 adolescents in Massachusetts and found that those living in more disadvantaged neighborhoods reported more mental health issues.
June 2026: Contributing Editor Rana Elmaghraby interviews Nadine Michel on a study that examined mental health, stressors, and protective factors among immigrant and nonimmigrant youth, suggesting cultural identity may help protect immigrant youth’s mental health and could inform future prevention and support efforts.
May 2026: Contributing Editor Deepika Shaligram interviews John E. Leikauf on a study that identified new attention-deficit/hyperactivity disorder (ADHD) subtypes using computerized attention-based tasks and compared these new subtypes’ responses to 2 ADHD medications: methylphenidate (stimulant) and atomoxetine (nonstimulant).
April 2026: Contributing Editor Janet Charoensook interviews Anick Bérard on possible risk of neurodevelopmental disorders in children exposed to acetaminophen in utero.
March 2026: Contributing Editor Aarya K. Rajalakshmi interviews Simon M. Wilksch on program effectiveness of Media Smart Targeted (MST) in 13- to 25-year-olds, including standard and flexible formats of program delivery, and evaluated impact on social media behaviors.
February 2026: Contributing Editor Jack Turban interviews Ben Singh on the effects of exercise on symptoms of anxiety and depression.
From the publisher's feed